Transglutaminase activation in neurodegenerative diseases

Future Neurology

Volumn 4, Issue 4, 2009, Pages 449-467

  Jeitner, Thomas M ^a   Muma, Nancy A ^b   Battaile, Kevin P ^c   Cooper, Arthur J L ^d  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Alzheimer's disease; Calcium; Huntington's disease; Neurogeneration; Parkinson's disease; Translutaminase

Indexed keywords

2,4 DIAMINOGLUTARIC ACID; AMINE; CALCIUM ION; CALMODULIN; CYSTAMINE; ENZYME INHIBITOR; KCA 075; KCC 009; MENADIONE; PENTAPEPTIDE; POLYGLUTAMINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE INHIBITOR; TYRPHOSTIN; UNCLASSIFIED DRUG; ZM 39923; ZM 49829;

AGING; ALZHEIMER DISEASE; CALCIUM BINDING; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; DEGENERATIVE DISEASE; DEPRESSION; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; MUTATIONAL ANALYSIS; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 69849106959     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/fnl.09.17     Document Type: Review

References (191)

1. Kim SY, Grant P, Lee JH et al.: Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease. J. Biol. Chem. 274, 30715-33021 (1999).
2. Citron BA, SantaCruz KS, Davies PJA et al.: Intron-exon swapping of transglutaminase mRNA and neuronal Tau aggregation in Alzheimer's disease. J. Biol. Chem. 276, 3295-3301 (2001).
3. Wilhelmus MM, Grunberg SC, Bol JG et al.: Transglutaminases and transglutaminase-catalyzed cross-links colocalize with the pathological lesions in Alzheimer's disease brain. Brain Pathol. DOI: 10.1111/ j.1750-3639.2008.00197.x (2008) (Epub ahead of print).
4. Hadjivassiliou M, Aeschlimann P, Strigun A et al.: Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. Ann. Neurol. 64, 332-343 (2008).
5. Lorand L, Graham RM: Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 4, 140-156 (2003).
6. Molberg Ø, MacAdam SN, Korner R et al.: Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med. 4, 713-717 (1998).
7. Van de Wal Y, Kooy Y, van Veelen P et al.: Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J. Immunol. 161, 1585-1588 (1998).
8. Nemes Z, Marekov LN, Fésüs L et al.: A novel function for transglutaminase 1: attachment of long-chain μ-hydroxyceramides to involucrin by ester bond formation. Proc. Natl Acad. Sci. USA 96, 8402-8407 (1999).
9. Folk JE, Park MH, Chung SI et al.: Polyamines as physiological substrates for transglutaminases. J. Biol. Chem. 255, 3695-3700 (1980).
10. Piacentini M, Martinet N, Beninati S et al.: Free and protein-conjugated polyamines in mouse epidermal cells. Effect of high calcium and retinoic acid. J. Biol. Chem. 263, 3790-3794 (1988).
11. Jeitner TM, Matson WR, Folk JE et al.: Increased levels of γ-glutamylamines in Huntington disease CSF. J. Neurochem. 106, 37-44 (2008).
12. ε-(γ-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. J. Neurochem. 79, 1109-1112 (2001).
13. Dedeoglu A, Kubilus JK, Jeitner TM et al.: Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 22, 8942-8950 (2002).
14. Lai TS, Tucker T, Burke JR et al.: Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats. J. Neurochem. 88, 1253-1260 (2004).
15. Konno T, Morii, T, Shimizu, H et al.: Paradoxical inhibition of protein aggregation and precipitation by transglutaminase-catalyzed intermolecular cross-linking. J. Biol. Chem. 280, 17520-17525 (2005).
16. Fink ML, Folk JE: γ-Glutamylamine cyclotransferase. An enzyme involved in the catabolism of ε-(γ-glutamyl)lysine and other γ-glutamylamines. Mol. Cell. Biochem. 38, 59-67 (1981).
17. Cordella-Miele E, Miele L, Beninati S et al.: Transglutaminase-catalyzed incorporation of polyamines into phospholipase A2. J. Biochem. 113, 164-173 (1993).
18. Masuda M, Betancourt L, Matsuzawa T et al.: Activation of rho through a cross-link with polyamines catalyzed by Bordetella dermonecrotizing toxin. EMBO J. 19, 521-530 (2000).
19. Masuda M, Minami M, Shime H et al.: In vivo modifications of small GTPase Rac and Cdc42 by Bordetella dermonecrotic toxin. Infect. Immun. 70, 998-1001 (2002).
20. Folk JE, Mullooly JP, Cole PW: Mechanism of action of guinea pig liver transglutaminase. II. The role of metal in enzyme activation. J. Biol. Chem. 242, 1838-1844 (1967).
21. Martinet N, Beninati S, Nigra TP et al.: N1N8-Bis(γ-glutamyl)spermidine cross-linking in epidermal-cell envelopes. Comparison of cross-link levels in normal and psoriatic cell envelopes. Biochem. J. 271, 305-308 (1990).
22. Murthy SN, Wilson J, Guy SL et al.: Intramolecular crosslinking of monomeric fibrinogen by tissue transglutaminase. Proc. Natl Acad. Sci. USA 88, 10601-10604 (1991).
23. ε(γ-glutamyl)lysine crosslinks in the blood clot of the horseshoe crab, Limulus polyphemus. Biochem. Biophys. Res. Commun. 188, 655-661 (1992).
24. Kuchibhotla KV, Goldman ST, Lattarulo CR et al.: Aβ plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 59, 214-225 (2008).
25. Zhang J, Lesort M, Guttmann RP et al.: Modulation of the in situ activity of tissue transglutaminase by calcium and GTP. J. Biol. Chem. 273, 2288-2295 (1998).
26. Tucholski J, Kuret J, Johnson GVW: Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination. J. Neurochem. 73, 1871-1880 (1999).
27. Casadio R, Polverini E, Mariani P et al.: The structural basis for the regulation of tissue transglutaminase by calcium ions. Eur. J. Biochem. 262, 672-679 (1999).
28. Ahvazi B, Kim HC, Kee SH et al.: Three-dimensional structure of the human transglutaminase 3 enzyme: binding of calcium ions changes structure for activation. EMBO J. 21, 2055-2067 (2002).
29. Liu S, Cerione RA, Clardy J: Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. Proc. Natl Acad. Sci. USA 99, 2743-2747 (2002).
30. Ahvazi B, Boeshans KM, Idler W et al.: Roles of calcium ions in the activation and activity of the transglutaminase 3 enzyme. J. Biol. Chem. 278, 23834-23841 (2003).
31. Boeshans KM, Mueser TC, Ahvazi B: A three-dimensional model of the human transglutaminase 1: insights into the understanding of lamellar ichthyosis. J. Mol. Model. 13, 233-246 (2007).
32. Pinkas DM, Strop P, Brunger AT et al.: Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol. 5, E327 (2007).
33. Andreotti AH: Native state proline isomerization: an intrinsic molecular switch. Biochemistry 42, 9515-9524 (2003).
34. Andreotti AH: Opening the pore hinges on proline. Nat. Chem. Biol. 2, 13-14 (2006).
35. Sarkar P, Reichman C, Saleh T et al.: Proline cis-trans isomerization controls autoinhibition of a signaling protein. Mol. Cell. 25, 413-426 (2007).
36. 1H NMR spectroscopy. Proc. Natl Acad. Sci. USA 86, 2195-2198 (1989).
37. 2+-dependent transamidation activity in the protection afforded by tissue transglutaminase against doxorubicin-induced apoptosis. Biochemistry 45, 13163-13174 (2006).
38. Sugimura Y, Hosono M, Wada F et al.: Screening for the preferred substrate sequence of transglutaminase using a phage-displayed peptide library: identification of peptide substrates for TGASE 2 and factor XIIIA. J. Biol. Chem. 281, 17699-17706 (2006).
39. Iismaa SE, Holman S, Wouters MA et al.: Evolutionary specialization of a tryptophan indole group for transition-state stabilization by eukaryotic transglutaminases. Proc. Natl Acad. Sci. USA 100, 12636-12641 (2003).
40. Eigel WN, Randolph HE: Preparation of whole γ-casein by treatment with calcium phosphate gel. J. Dairy. Sci. 57, 1444-1447 (1974).
41. Bungay PJ, Owen RA, Coutts IC et al.: A role for transglutaminase in glucose-stimulated insulin release from the pancreatic β-cell. Biochem. J. 235, 269-278 (1986).
42. Tiraboschi P, Hansen LA, Thal LJ et al.: The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62, 1984-1989 (2004).
43. Mattson MP: Pathways towards and away from Alzheimer's disease. Nature 430, 631-639 (2004).
44. Hardy J, Allsop D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12, 383-388 (1991).
45. Nistor M, Don M, Parekh M et al.: α- and β-secretase activity as a function of age and β-amyloid in Down syndrome and normal brain. Neurobiol. Aging 28, 1493-1506 (2007).
46. Holmes C, Boche D, Wilkinson D et al.: Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled Phase I trial. Lancet 372, 216-223 (2008).
47. Schmitz C, Rutten BP, Pielen A et al.: Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 164, 1495-1502 (2004).
48. Mudher A, Lovestone S: Alzheimer's disease - do tauists and baptists finally shake hands? Trends Neurosci. 25, 22-26 (2002).
49. Johnson GVW, Cox TM, Lockhart JP et al.: Transglutaminase activity is increased in Alzheimer's disease brain. Brain Res. 751, 323-329 (1997).
50. Singer SM, Norlund MA, Lee JM et al.: Transglutaminase cross-links in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease. Neurochem. Int. 40, 17-30 (2002).
51. Phillips MA, Jessen BA, Lu Y et al.: A distal region of the human TGM1 promoter is required for expression in transgenic mice and cultured keratinocytes. BMC Dermatol. 4, 2 (2004).
52. Ritter SJ, Davies PJ: Identification of a transforming growth factor-β1/bone morphogenetic protein 4 (TGF-β1/BMP4) response element within the mouse tissue transglutaminase gene promoter. J. Biol. Chem. 273, 12798-12806 (1998).
53. Kuncio GS, Tsyganskaya M, Zhu J et al.: TNF-α modulates expression of the tissue transglutaminase gene in liver cells. Am. J. Physiol. 274, G240-G245 (1998).
54. Park KC, Chung KC, Kim YS et al.: Transglutaminase 2 induces nitric oxide synthesis in BV-2 microglia. Biochem. Biophys. Res. Commun. 323, 1055-1062 (2004).
55. Campisi A, Caccamo D, Li Volti G et al.: Glutamate-evoked redox state alterations are involved in tissue transglutaminase upregulation in primary astrocyte cultures. FEBS. Lett. 578, 80-84 (2004).
56. Kim Y, Park YW, Lee YS et al.: Hyaluronic acid induces transglutaminase II to enhance cell motility; role of Rac1 and FAK in the induction of transglutaminase II. Biotechnol. Lett. 30, 31-39 (2008).
57. Festoff BW, SantaCruz K, Arnold PM et al.: Injury-induced 'switch' from GTP-regulated to novel GTP-independent isoform of tissue transglutaminase in the rat spinal cord. J. Neurochem. 81, 708-718 (2002).
58. Antonyak MA, Jansen JM, Miller AM et al.: Two isoforms of tissue transglutaminase mediate opposing cellular fates. Proc. Natl Acad. Sci. USA 103, 18609-18614 (2006).
59. Bonelli RM, Aschoff A, Niederwieser G et al.: Cerebrospinal fluid tissue transglutaminase as a biochemical marker for Alzheimer's disease. Neurobiol. Dis. 11, 106-110 (2002).
60. Vermes I, Steur EN, Jirikowski GF et al.: Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis. Mov. Disord. 19, 1252-1254 (2004).
61. Aeschlimann D, Mosher D, Paulsson M: Tissue transglutaminase and factor XIII in cartilage and bone remodeling. Semin. Thromb. Hemost. 22, 437-443 (1996).
62. Zemskov EA, Janiak A, Hang J et al.: The role of tissue transglutaminase in cell-matrix interactions. Front. Biosci. 11, 1057-1176 (2006).
63. El Nahas AM, Abo-Zenah H, Skill NJ et al.: Elevated ε-(γ-glutamyl)lysine in human diabetic nephropathy results from increased expression and cellular release of tissue transglutaminase. Nephron Clin. Pract. 97, C108-C117 (2004).
64. Siegel M, Strnad P, Watts RE et al.: Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury. PLoS ONE 3, E1861 (2008).
65. Jensen PH, Sørensen ES, Petersen TE et al.: Residues in the synuclein consensus motif of the α-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid βA4 peptide. Biochem. J. 310, 91-94 (1995).
66. Dudek SM, Johnson GVW: Transglutaminase facilitates the formation of polymers of the β-amyloid peptide. Brain Res. 651, 129-133 (1994).
67. Hartley DM, Zhao C, Speier AC et al.: Transglutaminase induces protofibril-like β-protein assemblies that are protease-resistant and inhibit long-term potentiation. J. Biol. Chem. 283, 16790-16800 (2008).
68. Abdalla S, Lother H, El Missiry A et al.: Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease. J. Biol. Chem. 284, 6554-6565 (2009).
69. Abdalla S, Lother H, El Missiry A et al.: Dominant negative AT2 receptor oligomers induce G-protein arrest and symptoms of neurodegeneration. J. Biol. Chem. 284, 6566-6574 (2009).
70. Cooper AJL, Sheu KR, Burke JR et al.: Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and α-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length. Proc. Natl Acad. Sci. USA 94, 12604-12609 (1997).
71. Gentile V, Sepe C, Calvani M et al.: Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases. Arch. Biochem. Biophys. 352, 314-321 (1998).
72. Cooper AJL, Wang J, Pasternack R et al.: Lysine-rich histone (H1) is a lysyl substrate of tissue transglutaminase: possible involvement of transglutaminase in the formation of nuclear aggregates in (CAG)n/Qn expansion diseases. Dev. Neurosci. 22, 404-417 (2000).
73. Nemes Z, Devreese B, Steinert PM et al.: Cross-linking of ubiquitin, HSP27, parkin, and α-synuclein by γ-glutamyl-ε-lysine bonds in Alzheimer's neurofibrillary tangles. FASEB J. 18, 1135-1137 (2004).
74. Norlund MA, Zainelli G, Lee J et al.: Elevated transglutaminase-induced bonds in Alzheimers PHF tau. Brain Res. 851, 154-163 (1999).
75. Appelt DM, Balin BJ: The association of tissue transglutaminase with human recombinant tau results in the formation of insoluble filamentous structures. Brain Res. 745, 21-31 (1997).
76. Dudek SM, Johnson GVW: Transglutaminase catalyzes the formation of sodium dodecyl sulfate-insoluble, Alz-50-reactive polymers of tau. J. Neurochem. 61, 1159-1162 (1993).
77. Miller ML, Johnson GVW: Transglutaminase cross-linking of the tau protein. J. Neurochem. 65, 1760-1770 (1995).
78. Murthy SN, Wilson JH, Lukas TJ et al. Cross-linking sites of the human tau protein, probed by reactions with human transglutaminase. J. Neurochem. 71, 2607-2614 (1998).
79. Wang DS, Dickson DW, Malter JS: Tissue Transglutaminase, protein cross-linking and Alzheimer's disease: review and views. Int. J. Clin. Exp. Pathol. 1, 5-18 (2008).
80. Junn E, Ronchetti RD, Quezado MM et al.: Tissue transglutaminase-induced aggregation of α-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 100, 2047-2052 (2003).
81. Schmid AW, Chiappe D, Pignat V et al.: Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of α-synuclein: implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. DOI: 10.1074/jbc.M809067200 (2009) (Epub ahead of print).
82. Segers-Nolten IM, Wilhelmus MM, Veldhuis G et al.: Tissue transglutaminase modulates α-synuclein oligomerization. Protein Sci. 17, 1395-1402 (2008).
83. Steinert PM, Kim SY, Chung SI et al.: The transglutaminase 1 enzyme is variably acylated by myristate and palmitate during differentiation in epidermal keratinocytes. J. Biol. Chem. 271, 26242-26250 (1996).
84. Kim SY, Chung SI, Steinert PM: Highly active soluble processed forms of the transglutaminase 1 enzyme in epidermal keratinocytes. J. Biol. Chem. 270, 18026-18035 (1995).
85. Nemes Z, Steinert PM: Bricks and mortar of the epidermal barrier. Exp. Mol. Med. 31, 5-19 (1999).
86. Busche MA, Eichhoff G, Adelsberger H et al.: Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 321, 1686-1689 (2008).
87. Tandon A, Fraser P: The presenilins. Genome Biol. 3, 3014 (2002).
88. 2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell 126, 981-993 (2006).
89. 2+ leak function of presenilin 1. J. Clin. Invest. 117, 1230-1239 (2007).
90. 2+ signals and altered membrane excitability. J. Neurosci. 24, 508-513 (2004).
91. 2+ disruptions in young, adult, and aged Alzheimer's disease mice. J. Neurosci. 26, 5180-5189 (2006).
92. Thibault O, Gant JC, Landfield PW: Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store. Aging Cell 6, 307-317 (2007).
93. 2+ channels and ryanodine receptors in heart cells. Nature 410, 592-596 (2001).
94. Oddo S, Caccamo A, Shepherd JD et al.: Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39, 409-421 (2003).
95. Gibson GE, Zhang H, Toral-Barza L et al.: Calcium stores in cultured fibroblasts and their changes with Alzheimer's disease. Biochim. Biophys. Acta 1316, 71-77 (1996).
96. Gusella JF, MacDonald ME: Hunting for Huntington's disease. Mol. Genet. Med. 3, 139-158 (1993).
97. Stine OC, Pleasant N, Franz ML et al.: Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. Hum. Mol. Genet. 2, 1547-1549 (1993).
98. Brandt J, Bylsma FW, Gross R et al.: Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology 46, 527-531 (1996).
99. DiFiglia M, Sapp E, Chase K et al.: Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14, 1075-1081 (1995).
100. Chen S, Berthelier V, Yang W et al.: Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J. Mol. Biol. 311, 173-182 (2001).
101. Green H: Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism. Cell 74, 955-956 (1993).
102. Kahlem P, Terré C, Green H et al.: Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system. Proc. Natl Acad. Sci. USA 93, 14580-14585 (1996).
103. Kahlem P, Green H, Djian P: Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol. Cell. 1, 595-601 (1998).
104. Karpuj MV, Garren H, Slunt H et al.: Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc. Natl Acad. Sci. USA 96, 7388-7393 (1999).
105. Cooper AJL, Jeitner TM, Gentile V et al.: Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG) n/Qn-expansion diseases? Neurochem. Int. 40, 53-67 (2002).
106. Zainelli GM, Dudek NL, Ross CA et al.: Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3. J. Neuropathol. Exp. Neurol. 64, 58-65 (2005).
107. Zainelli GM, Ross, CA, Troncoso JC et al.: Transglutaminase cross-links in intranuclear inclusions in Huntington disease. J. Neuropathol. Exp. Neurol. 62, 14-24 (2003).
108. Lesort M, Chun W, Johnson GVW et al.: Tissue transglutaminase is increased in Huntington's disease brain. J. Neurochem. 73, 2018-2027 (1999).
109. Lee J, Kim YS, Choi DH: Transglutaminase 2 induces nuclear factor-κB activation via a novel pathway in BV-2 microglia. J. Biol. Chem. 279, 53725-53735 (2004).
110. Zhang H, Das S, Li QZ et al.: Elucidating a normal function of huntingtin by functional and microarray ana lysis of huntingtin-null mouse embryonic fibroblasts. BMC Neurosci. 9, 38 (2008).
111. Tang TS, Tu H, Chan EY et al.: Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39, 227-239 (2003).
112. Cepeda C, Ariano MA, Calvert CR et al.: NMDA receptor function in mouse models of Huntington disease. J. Neurosci Res. 66, 525-539 (2001).
113. Zeron MM, Hansson O, Chen N et al.: Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33, 849-860 (2002).
114. Tang TS, Chen X, Liu J et al.: Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J. Neurosci. 27, 7899-7910 (2007).
115. Hodgson JG, Agopyan N, Gutekunst CA et al.: A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 23, 181-192 (1999).
116. Romero E, Cha GH, Verstreken P et al.: Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron 57, 27-40 (2008).
117. 2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol. Cell Biochem. 269, 143-152 (2005).
118. Panov AV, Gutekunst CA, Leavitt BR et al.: Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5, 731-736 (2005).
119. Milakovic T, Quintanilla RA, Johnson GVW: Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J. Biol. Chem. 281, 34785-34795 (2006).
120. Lim D, Fedrizzi L, Tartari M et al.: Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J. Biol. Chem. 283, 5780-5789 (2008).
121. Puszkin EG, Raghuraman V: Catalytic properties of a calmodulin-regulated transglutaminase from human platelet and chicken gizzard. J. Biol. Chem. 260, 16012-16020 (1985).
122. Billett HH, Puszkin EG: The red cell membrane contains calmodulin-regulated crosslinking and proteolytic activity. Hematol. Pathol. 5, 185-193 (1991).
123. Zainelli GM, Ross CA, Troncoso JC et al.: Calmodulin regulates transglutaminase 2 cross-linking of Huntingtin. J. Neurosci. 24, 1954-1961 (2004).
124. Dudek NL, Dai Y, Muma NA: Protective effects of interrupting the binding of calmodulin to mutant huntingtin. J. Neuropathol. Exp. Neurol. 67, 355-365 (2008).
125. Dudek NL, Dai Y, Muma NA: Neuroprotective effects of calmodulin peptide 76-121aa: disruption of calmodulin binding to mutant huntingtin. Brain Pathol. DOI:10.1111/j.1750-3639.2008.00258.x (2008) (In Press).
126. Mastroberardino PG, Iannicola C, Nardacci R et al.: 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ. 9, 873-880 (2002).
127. Liu P, Gupta N, Jing Y et al.: Age-related changes in polyamines in memory-associated brain structures in rats. Neuroscience 155, 789-796 (2008).
128. Kim SY, Jeitner TM, Steinert PM: Transglutaminases in disease. Neurochem. Int. 40, 85-103 (2002).
129. Muma NA: Transglutaminase is linked to neurodegenerative diseases. J. Neuropathol. Exp. Neurol. 66, 258-263 (2007).
130. Lees AJ: The Parkinson chimera. Neurology 72(Suppl. 7), S2-S11 (2009).
131. Mezey E, Dehejia A, Harta G et al.: α-synuclein in neurodegenerative disorders: murderer or accomplice? Nat. Med. 4, 755-757 (1998).
132. Spillantini MG, Schmidt ML, Lee VM et al.: a-synuclein in Lewy bodies. Nature 388, 839-840 (1997).
133. Arima K, Uéda K, Sunohara N et al.: Immunoelectron-microscopic demonstration of NACP/synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res. 808, 93-100 (1998).
134. Wirths O, Weickert S, Majtenyi K et al.: Lewy body variant of Alzheimer's disease: α-synuclein in dystrophic neurites of Aβ plaques. Neuroreport 11, 3737-3741 (2000).
135. Emadi S, Kasturirangan S, Wang MS et al.: Detecting morphologically distinct oligomeric forms of α-synuclein. J. Biol. Chem. DOI: 10.1074/jbc.M806559200 (2009) (Epub ahead of print).
136. Kragh CL, Lund LB, Febbraro F et al.: α-Synuclein aggregation and Ser129 phosphorylation dependent cell death in oligodendroglial cells. J. Biol. Chem. DOI: 10.1074/ jbc.M809671200 (2009) (Epub ahead of print).
137. Masliah E, Rockenstein E, Veinbergs I et al.: Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269 (2000).
138. Polymeropoulos MH, Lavedan C, Leroy E et al.: Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997).
139. Krüger R, Kuhn W, Müller T et al.: Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108 (1998).
140. Uversky VN: α-synuclein misfolding and neurodegenerative diseases. Curr. Protein Pept. Sci. 9, 507-540 (2008).
141. Andringa G, Lam, KY, Chegary M, Wang X et al.: Tissue transglutaminase catalyzes the formation of α-synuclein crosslinks in Parkinson's disease. FASEB J. 18, 932-934 (2004).
142. Bennett EJ, Shaler TA, Woodman B et al.: Global changes to the ubiquitin system in Huntington's disease. Nature 448, 704-708 (2007).
143. Wang J, Wang, CE, Orr A et al.: Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J. Cell Biol. 180, 1177-1189 (2008).
144. Mandrusiak LM, Beitel LK, Wang X et al.: Transglutaminase potentiates ligand-dependent proteasome dysfunction induced by polyglutamine-expanded androgen receptor. Hum. Mol. Genet. 12, 1497-1506 (2003).
145. Surmeier DJ: Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol. 6, 933-938 (2007).
146. Ibáñez-Sandoval O, Carrillo-Reid L, Galarraga E et al.: Bursting in substantia nigra pars reticulata neurons in vitro: possible relevance for Parkinson disease. J. Neurophysiol. 98, 2311-2323 (2007).
147. 2+]c dynamics in spontaneously firing dopamine neurons of the rat substantia nigra pars compacta. J. Cell Sci. 116, 2665-2675 (2003).
148. McMahon A, Wong BS, Iacopino AM et al.: Calbindin-D28k buffers intracellular calcium and promotes resistance to degeneration in PC12 cells. Brain Res. Mol. Brain Res. 54, 56-63 (1998).
149. Houghton DJ, Litvan I: Unraveling progressive supranuclear palsy: from the bedside back to the bench. Parkinsonism Relat. Disord. 13(Suppl. 3), S336-S340 (2007).
150. Zemaitaitis MO, Lee JM, Troncoso JC et al.: Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy. J. Neuropathol. Exp. Neurol. 59, 983-989 (2000).
151. Zemaitaitis MO, Kim SY, Halverson RA et al.: Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy. J. Neuropathol. Exp. Neurol. 62, 173-184 (2003).
152. Albers DS, Augood SJ: New insights into progressive supranuclear palsy. Trends Neurosci. 24, 347-353 (2001).
153. Walther DJ, Peter JU, Winter S et al.: Serotonylation of small GTPases is a signal transduction pathway that triggers platelet α-granule release. Cell 115, 851-862 (2003).
154. Dai Y, Dudek NL, Patel TB et al.: Transglutaminase-catalyzed transamidation: a novel mechanism for Rac1 activation by 5-hydroxytryptamine2A receptor stimulation. J. Pharmacol. Exp. Ther. 326, 153-162 (2008).
155. Lorand L, Conrad SM: Transglutaminases. Mol. Cell Biochem. 58, 9-35 (1984).
156. Jeitner TM, Delikatny EJ, Ahlqvist J et al.: Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem. Pharmacol. 69, 961-970 (2005).
157. Karpuj MV, Becher MW, Springer JE et al.: Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8, 143-149 (2002).
158. Van Raamsdonk JM, Pearson J, Bailey CDC et al.: Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J. Neurochem. 95, 210-220 (2005).
159. Stack EC, Ferro JL, Kim J et al.: Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease. Biochim. Biophys. Acta 1782, 151-162 (2008).
160. Fox JH, Barber DS, Singh B et al.: Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J. Neurochem. 91, 413-422 (2004).
161. Pinto JT, Van Raamsdonk JM, Leavitt BR et al.: Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. J. Neurochem. 94, 1087-1101 (2005).
162. Borrell-Pagès M, Canals JM, Cordelières FP et al.: Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J. Clin. Invest. 116, 1410-1424 (2006).
163. Jeitner TM, Pinto JT, Kranikov BF et al.: Transglutaminases and neurodegeneration. J. Neurochem. 109(Suppl. 1), 160-166 (2009).
164. Lesort M, Lee M, Tucholski J et al.: Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 278, 3825-3830 (2003).
165. Bailey CDC, Johnson GVW: The protective effects of cystamine in the R6/2 Huntington's disease mouse involves mechanisms other than the inhibition of tissue transglutaminase. Neurobiol. Aging 27, 871-879 (2006).
166. Goldstone SD, Fragonas JC, Jeitner TM et al.: Transcription factors as targets for oxidative signalling during lymphocyte activation. Biochim. Biophys. Acta 1263, 114-122 (1995).
167. Medvedev A, Saunders NA, Matsuura H et al.: Regulation of the transglutaminase I gene. Identification of DNA elements involved in its transcriptional control in tracheobronchial epithelial cells. J. Biol. Chem. 274, 3887-3896 (1999).
168. Lorand L, Rule NG, Ong HH et al.: Amine specificity in transpeptidation. Inhibition of fibrin cross-linking. Biochemistry 7, 1214-1223 (1968).
169. Curtis CG, Brown KL, Credo RB et al.: Calcium-dependent unmasking of active center cysteine during activation of fibrin stabilizing factor. Biochemistry 13, 3774-3780 (1974).
170. Gross M, Whetzel NK, Folk JE: Alkyl isocyanates as active site-directed inactivators of guinea pig liver transglutaminase. J. Biol. Chem. 250, 7693-7699 (1975).
171. Lee KN, Fésüs L, Yancey ST et al.: Development of selective inhibitors of transglutaminase. Phenylthiourea derivatives. J. Biol. Chem. 260, 14689-14694 (1985).
172. Lee KN, Chung SI, Girard JE et al.: Evaluation of phenylthiourea derivatives as inhibitors of transglutaminase-catalyzed reaction in Chinese hamster ovary cells. Biochim. Biophys. Acta 972, 120-130 (1988).
173. Auger M, McDermott AE, Robinson V et al.: Solid-state carbon-13 NMR study of a transglutaminase-inhibitor adduct. Biochemistry 32, 3930-3934 (1993).
174. Choi K, Siegel M, Piper JL et al.: Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem. Biol. 12, 469-475 (2005).
175. Watts RE, Siegel M, Khosla C: Structure-activity relationship ana lysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles. J. Med. Chem. 49, 7493-7501 (2009).
176. Killackey JJ, Bonaventura BJ, Castelhano AL et al.: A new class of mechanism-based inhibitors of transglutaminase enzymes inhibits the formation of cross-linked envelopes by human malignant keratinocytes. Mol. Pharmacol. 35, 701-706 (1989).
177. Pliura DH, Bonaventura BJ, Pauls HW et al.: Irreversible inhibition of transglutaminases by sulfonium methylketones: optimization of specificity and potency with μ-aminoacyl spacers. Enzyme Inhib. 6, 181-194 (1992).
178. Freund KF, Doshi KP, Gaul SL et al.: Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry 33, 10109-10119 (1994).
179. Marrano C, de Macédo P, Keillor JW: Evaluation of novel dipeptide-bound α,β-unsaturated amides and epoxides as irreversible inhibitors of guinea pig liver transglutaminase.
180. Marrano C, de Macédo P, Gagnon P et al.: Synthesis and evaluation of novel dipeptide-bound 1,2,4-thiadiazoles as irreversible inhibitors of guinea pig liver transglutaminase. Bioorgan. Med. Chem. 9, 3231-3241 (2001).
181. de Macédo P, Marrano C, Keillor JW: Synthesis of dipeptide-bound epoxides and α,β-unsaturated amides as potential irreversible transglutaminase inhibitors. Bioorgan. Med. Chem. 10, 355-360 (2002).
182. Case A, Ni J, Yeh LA, et al.: Development of a mechanism-based assay for tissue transglutaminase - results of a high-throughput screen and discovery of inhibitors. Anal. Biochem. 338, 237-244 (2005).
183. Case A, Stein RL: Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptide slow-binding inhibitor. Biochemistry 46, 1106-1115 (2007).
184. Duval E, Case A, Stein RL et al.: Structure-activity relationship study of novel tissue transglutaminase inhibitors. Bioorg. Med. Lett. 15, 185-189 (2005).
185. Lai T-S, Liu Y, Tucker T et al.: Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries. Chem. Biol. 15, 969-978 (2008).
186. Sohn J, KimTI, Yoon YH et al.: Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis. J. Clin. Invest. 111, 121-128 (2003).
187. McConoughey SJ, Chavez JC, Cooper AJL et al.: Release of transcriptional repression created by transglutaminase is protective in mutant huntingtin expressing neurons. Presented at: Annual Meeting of the Society for Neuroscience. San Diego, CA, USA, 3-7 November 2007.
188. McConoughey SJ, Nietsetskaya Z, Karpisheva K et al.: Transglutaminase 2 inhibition ameliorates transcriptional dysregulation in Huntington disease. Presented at: Annual Meeting of the Society for Neuroscience. Washington, DC, USA, 15-19 November 2008.
189. Gines S, Seong IS, Fossale E et al.: Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum. Mol. Gentet. 12, 497-508 (2003).
190. Yuan L, Choi K, Khosla C: Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol. Cancer Ther. 4, 1293-1302 (2005).
191. Yuan L, Siegel M, Choi K et al.: Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthoptic glioblastomas to chemotherapy. Oncogene 26, 2563-2573 (2007).